Study Drugs | Data |
---|---|
Breast | |
Capecitabine + lapatinib | Geyer et al., 200635 Zhou et al., 200936 |
Eribulin | Cortés et al., 201137 |
Exemestane + everolimus | Baselga et al., 201238 Burris et al., 201339 |
T-DM1 | Verma et al., 201240 Welslau et al., 201441 |
Trastuzumab + chemotherapy + pertuzumab | Cortés et al., 201342 Swain et al., 201543 |
Lung | |
Crizotinib | Solomon et al., 201444 |
Erlotinib | Rosell et al., 201245 |
Nivolumab | Brahmer et al., 201546 |
Pembrolizumab | Herbst et al., 201647 |
Pemetrexed | Belani et al., 201248 Ciuleanu et al., 200949 |
Prostate | |
Abiraterone + prednisone | De Bono et al., 201150 Harland et al., 201351 |
Cabazitaxel + prednisone | De Bono et al., 201052 |
Docetaxel (Q7 or Q21) prednisone | Berthold et al., 200853 Tannock et al., 200454 |
Enzalutamide | Fizazi et al., 201455 Scher et al., 201256 |
Mitoxantrone + prednisone | De Bono et al., 201052 |